These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18250304)

  • 1. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.
    Zhang SJ; Ma LY; Huang QH; Li G; Gu BW; Gao XD; Shi JY; Wang YY; Gao L; Cai X; Ren RB; Zhu J; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2076-81. PubMed ID: 18250304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gata2-L359V impairs primitive and definitive hematopoiesis and blocks cell differentiation in murine chronic myelogenous leukemia model.
    Fu YK; Tan Y; Wu B; Dai YT; Xu XG; Pan MM; Chen ZW; Qiao N; Wu J; Jiang L; Lu J; Chen B; Rein A; Izraeli S; Sun XJ; Huang JY; Huang QH; Chen Z; Chen SJ
    Cell Death Dis; 2021 Jun; 12(6):568. PubMed ID: 34078881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
    Zhao LJ; Wang YY; Li G; Ma LY; Xiong SM; Weng XQ; Zhang WN; Wu B; Chen Z; Chen SJ
    Blood; 2012 Mar; 119(12):2873-82. PubMed ID: 22318203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia.
    Shimamoto T; Ohyashiki K; Ohyashiki JH; Kawakubo K; Fujimura T; Iwama H; Nakazawa S; Toyama K
    Blood; 1995 Oct; 86(8):3173-80. PubMed ID: 7579412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.
    Zhang SJ; Shi JY; Li JY
    Leuk Res; 2009 Aug; 33(8):1141-3. PubMed ID: 19304323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leukemia mutations corrupt but do not abrogate GATA-2 function.
    Katsumura KR; Mehta C; Hewitt KJ; Soukup AA; Fraga de Andrade I; Ranheim EA; Johnson KD; Bresnick EH
    Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10109-E10118. PubMed ID: 30301799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional repression of c-Myb and GATA-2 is involved in the biologic effects of C/EBPalpha in p210BCR/ABL-expressing cells.
    Soliera AR; Lidonnici MR; Ferrari-Amorotti G; Prisco M; Zhang Y; Martinez RV; Donato NJ; Calabretta B
    Blood; 2008 Sep; 112(5):1942-50. PubMed ID: 18550858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
    Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
    Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of GATA-1 mRNA in human myeloid leukemic cells.
    Guerrasio A; Saglio G; Rosso C; Alfarano A; Camaschella C; Lo Coco F; Biondi A; Rambaldi A; Nicolis S; Ottolenghi S
    Leukemia; 1994 Jun; 8(6):1034-8. PubMed ID: 8207977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
    Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
    Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro.
    Sen S; Zhou H; Andersson BS; Cork A; Freireich EJ; Stass SA
    Cancer Genet Cytogenet; 1995 Jul; 82(1):35-40. PubMed ID: 7627932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
    Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
    Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia stem cells.
    Jamieson CH
    Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-lymphoid/myeloid stem cell origin in Ph-positive acute leukemia with myeloid markers.
    Akashi K; Taniguchi S; Nagafuji K; Harada M; Shibuya T; Hayashi S; Gondo H; Niho Y
    Leuk Res; 1993 Jul; 17(7):549-55. PubMed ID: 8326735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
    Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
    Melo JV; Goldman JM
    Leukemia; 1992 Aug; 6(8):786-90. PubMed ID: 1353550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of aberrant transcription factor in the progression of chronic myeloid leukemia.
    Zhang S
    Leuk Lymphoma; 2008 Aug; 49(8):1463-9. PubMed ID: 18766960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia.
    Cogswell PC; Morgan R; Dunn M; Neubauer A; Nelson P; Poland-Johnston NK; Sandberg AA; Liu E
    Blood; 1989 Dec; 74(8):2629-33. PubMed ID: 2684296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.